

Online Appendix: Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1

Table 1. Comparisons of Glucose (mg/dl) and C-Peptide (ng/ml) Values (Mean ± SD) between Parenteral and Oral Trial Participants at the Visit 30 Months Before Diagnosis

	Parenteral (n=22)	Oral (n=32)	P-Value*
Fasting Glucose	89 ± 11	88 ± 7	0.94
2-Hr Glucose	132 ± 37	118 ± 27	0.11
AUC Glucose	18726 ± 2318	16572 ± 2009	< 0.01
Fasting C-Peptide	0.95 ± 0.72	1.16 ± 0.82	0.33
Peak C-Peptide	4.41 ± 1.59	5.46 ± 2.50	0.07
AUC C-Peptide	399 ± 175	493 ± 220	0.10
<u>Fasting C-Peptide</u> (x 10 ³) Fasting Glucose	11 ± 8	13 ± 8	0.31
<u>Peak C-peptide</u> (x 10 ³) 2-Hr Glucose	35 ± 11	49 ± 23	<0.01
<u>AUC C-Peptide</u> (x 10 ³) AUC Glucose	21 ± 8	30 ± 13	<0.01

*For comparisons between Parenteral and Oral trial groups

Figure 1. The prevalence of glucose abnormalities (IFG, IGT and/or an unconfirmed diabetic OGTT) with progression for the parenteral and oral groups separately and combined. There tended to be increasing percentages of individuals with abnormalities with decreasing time to diagnosis. The percentage of those with abnormalities 6 months before diagnosis was >80% for both the parenteral and oral groups.

